Targets › NR2E3
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Ophthalmology; next expected readout Feb 2027.
Orphan nuclear receptor of retinal photoreceptor cells. Transcriptional factor that is an activator of rod development and repressor of cone development. (UniProt, Q9Y5X4)
Open in Phaseline: the race on NR2E3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ocugen | OCU400 Gene therapy vector for retinitis pigmentosa and Leber congenital amaurosis | RHO, NR2E3, CEP290 | Phase 3 | Retinitis Pigmentosa | Feb 2027 |
Retinitis Pigmentosa (2)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.